A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model

@article{Montonye2019APN,
  title={A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model},
  author={Michelle L. Montonye and Dan-dan Tian and Tarana Arman and Katherine D Lynch and Bruno Hagenbuch and Mary F. Paine and John D Clarke},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  year={2019},
  volume={371},
  pages={385 - 393}
}
Patients with nonalcoholic steatohepatitis (NASH) exhibit altered hepatic protein expression of metabolizing enzymes and transporters and altered xenobiotic pharmacokinetics. The botanical natural product silymarin, which has been investigated as a treatment of NASH, contains flavonolignans that inhibit organic anion–transporting polypeptide (OATP) transporter function. The purpose of this study was to assess the individual and combined effects of NASH and silymarin on the disposition of the… Expand
Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin‐drug interactions
TLDR
Data indicate that OATPs/Oatps contribute to flavonolignan cellular uptake and mediate the interaction between silymarin and NASH on pitavastatin systemic exposure. Expand
Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin
TLDR
Most human studies showed no silymarin–drug interactions explainable by these suggested interferences, and more interactions were found in animal studies, likely due to the much higher doses administered. Expand
Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary
TLDR
The NaPDI Center has two overarching goals: develop Recommended Approaches to guide researchers in the proper conduct of NPDI studies, which will evolve over time concurrent with emerging technologies and new research data, and apply the recommended approaches in evaluating four model NPs as precipitants of N PDIs with clinically relevant object drugs. Expand
Sub-chronic microcystin-LR renal toxicity in rats fed a high fat/high cholesterol diet.
TLDR
The data suggest an HFHC diet may increase the severity of certain MCLR-elicited renal toxicities, and the general concordance between KIM-1, polyuria, proteinuria, and renal casts after MclR exposure suggests that proximal tubule cell damage contributed to these connected pathologies. Expand
Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy
TLDR
Comparing single and multi-factorial PK interactions in precision drug therapy requires advances in clinical decision tools, intentional PK study designs, drug-metabolizing enzyme and transporter fractional contribution determinations, systems and computational approaches, and PK phenotyping of progressive diseases. Expand

References

SHOWING 1-10 OF 55 REFERENCES
Transporter‐Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate
TLDR
MEB hepatic CLuptake was reduced in NASH and also in healthy subjects with SLCO1B1 *15/*15 and *1A/*15 genotypes and the pharmacokinetics of drugs that are OATP1B 1/1B3 and MRP2 substrates may be substantially altered in NASh. Expand
The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity
TLDR
It is suggested that the pharmacokinetics of silymarin is altered in patients with liver disease, and patients with cirrhosis had the highest plasma caspase-3/7 activity and also achieved the highest exposures for the major sily marin flavonolignans. Expand
Gene-by-Environment Interaction of Bcrp−/− and Methionine- and Choline-Deficient Diet–Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition
TLDR
Data indicate that Bcrp is not solely responsible for SN-38 biliary efflux, but rather implicate a combined role for BCRP and MRP2, and may result in variable drug response to irinotecan therapy in polymorphic patients. Expand
Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression
TLDR
Assessment of the metabolism and disposition of SIM in a diet-induced rodent model of NASH suggest that NASH-mediated transporter regulation may play a role in altered SIMA disposition and the occurrence of myopathy. Expand
Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C
TLDR
The efficacy of silymarin may be more readily observed in NAFLD patients because of their higher flavonolignan plasma concentrations and more extensive enterohepatic cycling compared with those in HCV patients. Expand
Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis
TLDR
The combination of induced expression and altered localization of efflux transporters in NASH shifts the disposition profile of EZE-GLUC toward plasma retention away from the site of action, which may have implications for the pharmacological effect and safety of numerous drugs. Expand
Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis
TLDR
Increased metabolism and altered transporter regulation in NASH provide a mechanistic basis for interindividual variability in morphine disposition that may lead to opioid-related toxicity. Expand
Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract
TLDR
It is suggested that, after oral administration, silymarin flavonolignans are quickly metabolized to their conjugate, primarily forming glucuronides, and the conjugates are primary components present in human plasma. Expand
An Assessment of Pharmacokinetics and Antioxidant Activity of Free Silymarin Flavonolignans in Healthy Volunteers: A Dose Escalation Study
TLDR
The present study evaluated the pharmacokinetics of the six major flavonolignans in healthy volunteers receiving single doses of either one (175 mg), two (350 mg), or three (525 mg) milk thistle capsule(s) on three separate study visits, and demonstrated that all six flavons were rapidly absorbed and eliminated. Expand
Identification of Diet-Derived Constituents as Potent Inhibitors of Intestinal Glucuronidation
TLDR
A working systematic framework was applied to a panel of structurally diverse diet-derived constituents/extracts as inhibitors of intestinal UDP-glucuronosyl transferases (UGTs) to identify and characterize additional perpetrators of dietary substance–drug interactions that warrant advanced modeling and simulation to inform clinical assessment. Expand
...
1
2
3
4
5
...